SERIOUS adverse drug reactions are frequently recognized only after postmarketing surveillance has begun. The most common cause of drug restriction or drug withdrawal from the marketplace is prolongation of the QT interval with an associated finding of polymorphic ventricular tachycardia, also known as torsades de pointes (TdP). At least nine structurally unrelated drugs have been removed from the US market or have had their use severely limited. In this issue of Anesthesiology, Han etal. have demonstrated a dose-response relationship between sevoflurane and QTc prolongation.
展开▼
